Otezla revenue trends
In 1Q18, Celgene’s (CELG) Otezla generated revenue of $353 million compared to $242 million in 1Q17, which reflected a ~46% rise YoY (year-over-year) and a ~5% fall quarter-over-quarter.
In 1Q18, in US and international markets, Otezla generated revenues of $276 million and $77 million, respectively, compared to $199 million and $43 million, respectively, in 1Q17, which reflected rises of ~38.7% and ~79.1%, respectively, YoY.
Higher demand, the rise in the total number of prescriptions of Otezla in the US market, improved access, and market expansion primarily contributed to Otezla’s revenue growth in 1Q18.
Celgene anticipates revenue of $1.5 billion from the sales of Otezla in 2018.
In February, Celgene presented the data from its Phase 3 RELIEF trial at the American Academy of Dermatology’s annual meeting. Celgene conducted the Phase 3 RELIEF trial to evaluate the safety and efficacy of Otezla in the treatment of individuals with active Behcet’s disease with oral ulcers.
In the RELIEF clinical trial, patients on Otezla demonstrated a statistically significant decrease in oral ulcers compared to patients receiving the placebo.
In February, at the 13th Congress of ECCO (European Crohn’s and Colitis Organisation) in Vienna, Celgene also announced the results of its Phase 2 trial evaluating the safety and efficacy of Otezla in individuals with active ulcerative colitis who had failed at least one conventional therapy but were treatment-naïve to biological therapy.
In the trial, 21.8% of patients receiving Otezla 40 mg achieved TMS (Total Mayo Score) clinical remission at week 12 compared to 13.8% of patients in the placebo group.
In the trial, 31.6% of patients receiving Otezla 30 mg achieved TMS clinical remission compared to 13.8% of patients in the placebo group.